DocMorris AGXSWX:DOCM +1.65%65 3-Year EBITDA Growth Rate is 42.20% as of Jun. 2025, which is 1407% above its 10-year median of 2.80. GuruFocus rates XSWX:DOCM with a GF Score™ of 65/100 and a GF Value™ of CHF10.56 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 531 Healthcare Providers & Services companies, DocMorris AG ranks better than 86.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of DocMorris AG was 42.50% per year. The lowest was -90.70% per year. And the median was 2.80% per year.
DocMorris AG (XSWX:DOCM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
DocMorris AG 3-Year EBITDA Growth Rate Related Terms
DocMorris AG 3-Year EBITDA Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, DocMorris AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where DocMorris AG's 3-Year EBITDA Growth Rate falls into.
DocMorris AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.20% mean?
DocMorris AG (XSWX:DOCM) has a 3-Year EBITDA Growth Rate of 42.20% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DocMorris AG and its competitors. This is 1407% above median its historical median of 2.80. According to the industry distribution chart, DocMorris AG ranks #70 out of 531 companies in the Healthcare Providers & Services industry, placing it in the top 13.2%.
Is DocMorris AG's 3-Year EBITDA Growth Rate too high?
DocMorris AG's current 3-Year EBITDA Growth Rate of 42.20% is 1407% above median its 10-year median of 2.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. DocMorris AG's value of 42.20% is 326.3% above this industry median. Based on the distribution chart, DocMorris AG ranks #70 out of 531 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #70 out of 531 companies for 3-Year EBITDA Growth Rate. This places DocMorris AG in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 9.90. DocMorris AG's value of 42.20% is 326.3% above this benchmark. While the company's 10-year median is 2.80 vs. the industry median of 9.90, DocMorris AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 531 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocMorris AG's current 3-Year EBITDA Growth Rate of 42.20% is 326.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current 3-Year EBITDA Growth Rate is 42.20%, which is 1407% above median its own 10-year median of 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.56, compared to a current price of CHF9.25 — trading 12.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 42.20%, which is 1407% above median its 10-year median of 2.80 and 326.3% above the Healthcare Providers & Services industry median of 9.90. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current 3-Year EBITDA Growth Rate is 42.20% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF9.25 is trading 12.4% below its estimated GF Value™ of CHF10.56.
GuruFocus considers DocMorris AG to be Modestly Undervalued.
Key valuation signals for XSWX:DOCM:
3-Year EBITDA Growth Rate: 42.20% (1407% above median its 10-year median of 2.80)
GF Value™: CHF10.56 vs. price of CHF9.25 (12.4% below fair value)
Industry Position: 326.3% above the Healthcare Providers & Services median (#70 of 531)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 